BioSpace News Archive

Chi-Med Initiates Fruquintinib U.S. Clinical Trials

Chi-Med has initiated the United States Phase I bridging clinical trial of fruquintinib.

December 15, 2017

·

5 min read

Biotech Beach

TrovaGene today announced the pricing of a public offering of 15,000,000 shares of its common stock and common warrants to purchase up to an aggregate of 15,000,000 shares of common stock.

December 15, 2017

·

4 min read

FDA

Egalet Receives FDA Tentative Approval for Expanded Label for ARYMO ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated With Abuse-Deterrent Properties for Treatment of Chronic Pain

The FDA has issued tentative approval for a supplement submitted earlier in 2017 to update the ARYMO ER prescribing information with data from a Category 2/3 intranasal HAP study and an intranasal abuse-deterrent claim.

December 15, 2017

·

13 min read

Drug Development

Swedish Cell Therapy Candidate CellProtect has Received Orphan Drug Designation for the Treatment of Multiple Myeloma

The work on a clinical trial report to the Swedish Medical Products Agency is on-going and the plan is to publish the results in 2018.

December 15, 2017

·

3 min read

Drug Development

H3 Biomedicine’s Preclinical Data Highlighting Novel Discovery Research in Hepatocellular Carcinoma Published in December Issue of Cancer Research

The data were recently presented at the International Liver Cancer Association annual meeting held in Seoul, Republic of Korea.

December 15, 2017

·

3 min read

Chicago's Attune Medical Scores $10M Series C

Business

Bay Area Rigel’s CFO to Exit, Effective Dec. 31, 2017

Nelson Cabatuan, Rigel’s vice president, finance will serve as the company’s interim principal accounting officer.

December 15, 2017

·

3 min read

TESARO Announces U.S. FDA Approval of VARUBI IV fo

Drug Development

Finally Some Good News as the FDA Lifts Hold on Sanofi, Alnylam’s Fitusiran

Clinical trial dosing will resume around year-end 2017.

December 15, 2017

·

8 min read

Dana-Farber Cancer Institute Joins the Parker Inst

Business

In the Nick of Time: Galapagos Nabs Co-Promotion Filgotinib Deal With Gilead

Galapagos assumes 35% of the co-promotion efforts in Germany, France, Italy, Spain, the United Kingdom, the Netherlands, Belgium, and Luxembourg.

December 15, 2017

·

6 min read

Pharm Country

Pfizer Inc. Announces Expiration and Results of Its Private Exchange Offer for Its 6.500 Per Cent. Notes Due 2038 and Related Tender Offer

Pfizer announced the expiration and results of its previously announced offers to exchange and to repurchase any and all of its outstanding £1,500,000,000 6.500 per cent.

December 15, 2017

·

11 min read

Drug Development

IntelGenx Receives Health Canada Clearance to Begin Phase IIa Study With Montelukast Versafilm in Mild to Moderate Alzheimer’s Disease

The phase 2a proof of concept clinical study will start screening AD patients in Q1 2018.

December 15, 2017

·

4 min read